Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 35 entries
Sorted by: Best Match Show Resources per page
Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose.

American heart journal

Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN.
PMID: 34736855
Am Heart J. 2021 Nov 01;245:19-28. doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01.

BACKGROUND: Ticagrelor is often administered to patients with acute coronary syndromes. However, when these patients require urgent or emergent cardiothoracic (CT) surgery the presence of ticagrelor significantly increases surgical bleeding. The goal of the current trial is to evaluate...

Cite
Gibson CM, Mack MJ, Lee VT, et al. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. Am Heart J. 2021;245:19-28doi: 10.1016/j.ahj.2021.10.188.
Gibson, C. M., Mack, M. J., Lee, V. T., Schneider, D. J., Sellke, F. W., Ohman, E. M., Thourani, V. H., Doros, G., Kroger, H., Cutlip, D. E., & Deliargyris, E. N. (2021). Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. American heart journal, 24519-28. https://doi.org/10.1016/j.ahj.2021.10.188
Gibson, C Michael, et al. "Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose." American heart journal vol. 245 (2021): 19-28. doi: https://doi.org/10.1016/j.ahj.2021.10.188
Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. Am Heart J. 2021 Nov 01;245:19-28. doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01. PMID: 34736855.
Copy Download .nbib Format: NLM
Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose.

American heart journal

Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN.
PMID: 34736855
Am Heart J. 2021 Nov 01;245:19-28. doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01.

BACKGROUND: Ticagrelor is often administered to patients with acute coronary syndromes. However, when these patients require urgent or emergent cardiothoracic (CT) surgery the presence of ticagrelor significantly increases surgical bleeding. The goal of the current trial is to evaluate...

Cite
Gibson CM, Mack MJ, Lee VT, et al. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. Am Heart J. 2021;245:19-28doi: 10.1016/j.ahj.2021.10.188.
Gibson, C. M., Mack, M. J., Lee, V. T., Schneider, D. J., Sellke, F. W., Ohman, E. M., Thourani, V. H., Doros, G., Kroger, H., Cutlip, D. E., & Deliargyris, E. N. (2021). Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. American heart journal, 24519-28. https://doi.org/10.1016/j.ahj.2021.10.188
Gibson, C Michael, et al. "Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose." American heart journal vol. 245 (2021): 19-28. doi: https://doi.org/10.1016/j.ahj.2021.10.188
Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. Am Heart J. 2021 Nov 01;245:19-28. doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01. PMID: 34736855.
Copy Download .nbib Format: NLM
A Case Report of Kratom-Induced Psychosis.

Cureus

Cutlip HA, Bushman E, Thottumari L, Mogallapu R, Ang-Rabanes M.
PMID: 34367743
Cureus. 2021 Jun 30;13(6):e16073. doi: 10.7759/cureus.16073. eCollection 2021 Jun.

This case report details a patient with a complex medical history who was brought for psychiatric evaluation. An abrupt switch in Kratom use patterns was identified as the most likely causative factor of his symptoms. Adrenal insufficiency and posttraumatic...

Cite
Cutlip HA, Bushman E, Thottumari L, et al. A Case Report of Kratom-Induced Psychosis. Cureus. 2021;13(6):e16073doi: 10.7759/cureus.16073.
Cutlip, H. A., Bushman, E., Thottumari, L., Mogallapu, R., & Ang-Rabanes, M. (2021). A Case Report of Kratom-Induced Psychosis. Cureus, 13(6), e16073. https://doi.org/10.7759/cureus.16073
Cutlip, Hunter A, et al. "A Case Report of Kratom-Induced Psychosis." Cureus vol. 13,6 (2021): e16073. doi: https://doi.org/10.7759/cureus.16073
Cutlip HA, Bushman E, Thottumari L, Mogallapu R, Ang-Rabanes M. A Case Report of Kratom-Induced Psychosis. Cureus. 2021 Jun 30;13(6):e16073. doi: 10.7759/cureus.16073. eCollection 2021 Jun. PMID: 34367743; PMCID: PMC8330393.
Copy Download .nbib Format: NLM
Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose.

American heart journal

Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN.
PMID: 34736855
Am Heart J. 2021 Nov 01;245:19-28. doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01.

BACKGROUND: Ticagrelor is often administered to patients with acute coronary syndromes. However, when these patients require urgent or emergent cardiothoracic (CT) surgery the presence of ticagrelor significantly increases surgical bleeding. The goal of the current trial is to evaluate...

Cite
Gibson CM, Mack MJ, Lee VT, et al. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. Am Heart J. 2021;245:19-28doi: 10.1016/j.ahj.2021.10.188.
Gibson, C. M., Mack, M. J., Lee, V. T., Schneider, D. J., Sellke, F. W., Ohman, E. M., Thourani, V. H., Doros, G., Kroger, H., Cutlip, D. E., & Deliargyris, E. N. (2021). Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. American heart journal, 24519-28. https://doi.org/10.1016/j.ahj.2021.10.188
Gibson, C Michael, et al. "Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose." American heart journal vol. 245 (2021): 19-28. doi: https://doi.org/10.1016/j.ahj.2021.10.188
Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. Am Heart J. 2021 Nov 01;245:19-28. doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01. PMID: 34736855.
Copy Download .nbib Format: NLM
Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose.

American heart journal

Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN.
PMID: 34736855
Am Heart J. 2021 Nov 01;245:19-28. doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01.

BACKGROUND: Ticagrelor is often administered to patients with acute coronary syndromes. However, when these patients require urgent or emergent cardiothoracic (CT) surgery the presence of ticagrelor significantly increases surgical bleeding. The goal of the current trial is to evaluate...

Cite
Gibson CM, Mack MJ, Lee VT, et al. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. Am Heart J. 2021;245:19-28doi: 10.1016/j.ahj.2021.10.188.
Gibson, C. M., Mack, M. J., Lee, V. T., Schneider, D. J., Sellke, F. W., Ohman, E. M., Thourani, V. H., Doros, G., Kroger, H., Cutlip, D. E., & Deliargyris, E. N. (2021). Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. American heart journal, 24519-28. https://doi.org/10.1016/j.ahj.2021.10.188
Gibson, C Michael, et al. "Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose." American heart journal vol. 245 (2021): 19-28. doi: https://doi.org/10.1016/j.ahj.2021.10.188
Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. Am Heart J. 2021 Nov 01;245:19-28. doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01. PMID: 34736855.
Copy Download .nbib Format: NLM
The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

Meredith IT, Worthley S, Whitbourn R, Walters D, Popma J, Cutlip D, Fitzgerald P.
PMID: 19737684
EuroIntervention. 2007 May;3(1):50-3.

AIMS: To demonstrate the safety, performance and efficacy of the Endeavor Resolute stent in the treatment of patients with multiple-vessel as well as single-vessel coronary artery disease but where only one lesion per patient was treated.METHODS AND RESULTS: 130...

Cite
Meredith IT, Worthley S, Whitbourn R, et al. The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroIntervention. 2007;3(1):50-3
Meredith, I. T., Worthley, S., Whitbourn, R., Walters, D., Popma, J., Cutlip, D., & Fitzgerald, P. (2007). The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 3(1), 50-3.
Meredith, Ian T, et al. "The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial." EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology vol. 3,1 (2007): 50-3.
Meredith IT, Worthley S, Whitbourn R, Walters D, Popma J, Cutlip D, Fitzgerald P. The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroIntervention. 2007 May;3(1):50-3. PMID: 19737684.
Copy Download .nbib Format: NLM
Comparison of the CardioShield filter with the guardwire balloon in the prevention of embolisation during vein graft intervention: results from the CAPTIVE randomised trial.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

Holmes DR, Coolong A, O'Shaughnessy C, Chauhan M, Van Langenhove G, Hall P, Vermeersch P, Verlee P, Popma JJ, Cutlip D, Kuntz RE.
PMID: 19755255
EuroIntervention. 2006 Aug;2(2):161-8.

AIMS: This study assessed safety and efficacy of a third-generation distal protection device, MedNova CardioShield Bare Wire Myocardial Protection System, for treating Saphenous Vein Graft (SVG) disease.Treatment of SVG disease remains difficult, with increased adverse cardiac events (MACE) primarily...

Cite
Holmes DR, Coolong A, O'Shaughnessy C, et al. Comparison of the CardioShield filter with the guardwire balloon in the prevention of embolisation during vein graft intervention: results from the CAPTIVE randomised trial. EuroIntervention. 2006;2(2):161-8
Holmes, D. R., Coolong, A., O'Shaughnessy, C., Chauhan, M., Van Langenhove, G., Hall, P., Vermeersch, P., Verlee, P., Popma, J. J., Cutlip, D., & Kuntz, R. E. (2006). Comparison of the CardioShield filter with the guardwire balloon in the prevention of embolisation during vein graft intervention: results from the CAPTIVE randomised trial. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2(2), 161-8.
Holmes, David R, et al. "Comparison of the CardioShield filter with the guardwire balloon in the prevention of embolisation during vein graft intervention: results from the CAPTIVE randomised trial." EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology vol. 2,2 (2006): 161-8.
Holmes DR, Coolong A, O'Shaughnessy C, Chauhan M, Van Langenhove G, Hall P, Vermeersch P, Verlee P, Popma JJ, Cutlip D, Kuntz RE. Comparison of the CardioShield filter with the guardwire balloon in the prevention of embolisation during vein graft intervention: results from the CAPTIVE randomised trial. EuroIntervention. 2006 Aug;2(2):161-8. PMID: 19755255.
Copy Download .nbib Format: NLM
Magnetic resonance imaging of graded skeletal muscle injury in live rats.

Environmental health insights

Cutlip RG, Hollander MS, Johnson GA, Johnson BW, Friend SA, Baker BA.
PMID: 25525369
Environ Health Insights. 2014 Nov 20;8:31-9. doi: 10.4137/EHI.S15255. eCollection 2014.

INTRODUCTION: Increasing number of stretch-shortening contractions (SSCs) results in increased muscle injury.METHODS: Fischer Hybrid rats were acutely exposed to an increasing number of SSCs in vivo using a custom-designed dynamometer. Magnetic resonance imaging (MRI) imaging was conducted 72 hours...

Cite
Cutlip RG, Hollander MS, Johnson GA, et al. Magnetic resonance imaging of graded skeletal muscle injury in live rats. Environ Health Insights. 2014;8:31-9doi: 10.4137/EHI.S15255.
Cutlip, R. G., Hollander, M. S., Johnson, G. A., Johnson, B. W., Friend, S. A., & Baker, B. A. (2014). Magnetic resonance imaging of graded skeletal muscle injury in live rats. Environmental health insights, 831-9. https://doi.org/10.4137/EHI.S15255
Cutlip, Robert G, et al. "Magnetic resonance imaging of graded skeletal muscle injury in live rats." Environmental health insights vol. 8 (2014): 31-9. doi: https://doi.org/10.4137/EHI.S15255
Cutlip RG, Hollander MS, Johnson GA, Johnson BW, Friend SA, Baker BA. Magnetic resonance imaging of graded skeletal muscle injury in live rats. Environ Health Insights. 2014 Nov 20;8:31-9. doi: 10.4137/EHI.S15255. eCollection 2014. PMID: 25525369; PMCID: PMC4241962.
Copy Download .nbib Format: NLM
Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel.

Journal of the American College of Cardiology

Capodanno D, Morice MC, Angiolillo DJ, Bhatt DL, Byrne RA, Colleran R, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock SJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhovel U, Krucoff MW, Urban P, Mehran R.
PMID: 32943165
J Am Coll Cardiol. 2020 Sep 22;76(12):1468-1483. doi: 10.1016/j.jacc.2020.06.085.

Investigating the balance of risk for thrombotic and bleeding events after percutaneous coronary intervention (PCI) is especially relevant for patients at high bleeding risk (HBR). The Academic Research Consortium for HBR recently proposed a consensus definition in an effort...

Cite
Capodanno D, Morice MC, Angiolillo DJ, et al. Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel. J Am Coll Cardiol. 2020;76(12):1468-1483doi: 10.1016/j.jacc.2020.06.085.
Capodanno, D., Morice, M. C., Angiolillo, D. J., Bhatt, D. L., Byrne, R. A., Colleran, R., Cuisset, T., Cutlip, D., Eerdmans, P., Eikelboom, J., Farb, A., Gibson, C. M., Gregson, J., Haude, M., James, S. K., Kim, H. S., Kimura, T., Konishi, A., Leon, M. B., Magee, P. F. A., Mitsutake, Y., Mylotte, D., Pocock, S. J., Rao, S. V., Spitzer, E., Stockbridge, N., Valgimigli, M., Varenne, O., Windhovel, U., Krucoff, M. W., Urban, P., & Mehran, R. (2020). Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel. Journal of the American College of Cardiology, 76(12), 1468-1483. https://doi.org/10.1016/j.jacc.2020.06.085
Capodanno, Davide, et al. "Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel." Journal of the American College of Cardiology vol. 76,12 (2020): 1468-1483. doi: https://doi.org/10.1016/j.jacc.2020.06.085
Capodanno D, Morice MC, Angiolillo DJ, Bhatt DL, Byrne RA, Colleran R, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock SJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhovel U, Krucoff MW, Urban P, Mehran R. Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel. J Am Coll Cardiol. 2020 Sep 22;76(12):1468-1483. doi: 10.1016/j.jacc.2020.06.085. PMID: 32943165.
Copy Download .nbib Format: NLM
Experimental crystal violet and methyl violet poisoning in dogs and cattle.

Canadian journal of comparative medicine and veterinary science

Cutlip RC, Monlux WS.
PMID: 17649583
Can J Comp Med Vet Sci. 1967 Mar;31(3):80-4.

Crystal violet has been observed to cause fatal pulmonary alterations in dogs. To further evaluate this toxicity and the toxicity of methyl violet, 12 dogs and 2 calves were given 1 percent aqueous solutions of the dyes intravenously. Both...

Cite
Cutlip RC, Monlux WS. Experimental crystal violet and methyl violet poisoning in dogs and cattle. Can J Comp Med Vet Sci. 1967;31(3):80-4
Cutlip, R. C., & Monlux, W. S. (1967). Experimental crystal violet and methyl violet poisoning in dogs and cattle. Canadian journal of comparative medicine and veterinary science, 31(3), 80-4.
Cutlip, R C, and Monlux, W S. "Experimental crystal violet and methyl violet poisoning in dogs and cattle." Canadian journal of comparative medicine and veterinary science vol. 31,3 (1967): 80-4.
Cutlip RC, Monlux WS. Experimental crystal violet and methyl violet poisoning in dogs and cattle. Can J Comp Med Vet Sci. 1967 Mar;31(3):80-4. PMID: 17649583; PMCID: PMC1494643.
Copy Download .nbib Format: NLM
ROSES - Avoiding the thorns.

Cardiovascular revascularization medicine : including molecular interventions

Cutlip DE.
PMID: 34952821
Cardiovasc Revasc Med. 2021 Dec 16; doi: 10.1016/j.carrev.2021.12.014. Epub 2021 Dec 16.

No abstract available.

Cite
Cutlip DE. ROSES - Avoiding the thorns. Cardiovasc Revasc Med. 2021;doi: 10.1016/j.carrev.2021.12.014.
Cutlip, D. E. (2021). ROSES - Avoiding the thorns. Cardiovascular revascularization medicine : including molecular interventions, . https://doi.org/10.1016/j.carrev.2021.12.014
Cutlip, Donald E. "ROSES - Avoiding the thorns." Cardiovascular revascularization medicine : including molecular interventions vol. (2021). doi: https://doi.org/10.1016/j.carrev.2021.12.014
Cutlip DE. ROSES - Avoiding the thorns. Cardiovasc Revasc Med. 2021 Dec 16; doi: 10.1016/j.carrev.2021.12.014. Epub 2021 Dec 16. PMID: 34952821.
Copy Download .nbib Format: NLM
Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose.

American heart journal

Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN.
PMID: 34736855
Am Heart J. 2021 Nov 01;245:19-28. doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01.

BACKGROUND: Ticagrelor is often administered to patients with acute coronary syndromes. However, when these patients require urgent or emergent cardiothoracic (CT) surgery the presence of ticagrelor significantly increases surgical bleeding. The goal of the current trial is to evaluate...

Cite
Gibson CM, Mack MJ, Lee VT, et al. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. Am Heart J. 2021;245:19-28doi: 10.1016/j.ahj.2021.10.188.
Gibson, C. M., Mack, M. J., Lee, V. T., Schneider, D. J., Sellke, F. W., Ohman, E. M., Thourani, V. H., Doros, G., Kroger, H., Cutlip, D. E., & Deliargyris, E. N. (2021). Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. American heart journal, 24519-28. https://doi.org/10.1016/j.ahj.2021.10.188
Gibson, C Michael, et al. "Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose." American heart journal vol. 245 (2021): 19-28. doi: https://doi.org/10.1016/j.ahj.2021.10.188
Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. Am Heart J. 2021 Nov 01;245:19-28. doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01. PMID: 34736855.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 35 entries